Parenting and CAH - 21-hydroxylase Deficiency

Launched by ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS · Mar 21, 2025

Keywords

ClinConnect Summary

This clinical trial is studying how the genetic condition known as congenital adrenal hyperplasia (CAH), specifically the 21-hydroxylase deficiency (21OHD) type, affects women, particularly in terms of their sexuality, fertility, and pregnancy outcomes. CAH is caused by a problem with a gene that helps the body produce certain hormones. The trial aims to gather more information about how this condition impacts women and their experiences, as there is currently limited data available.

To be eligible for this trial, participants must be women aged 18 or older who have been genetically confirmed to have 21-hydroxylase deficiency. They should also be able to understand and agree to participate in the research. Unfortunately, women who do not speak French or who are under legal protection cannot join the study. Those who participate can expect to share their experiences and possibly receive information that could help improve care for others with this condition. Overall, this trial hopes to shed light on important aspects of living with CAH and to improve the support and treatment options available for affected women.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Patients aged 18 or over
• • Patients with HCS due to 21-hydroxylase deficiency, confirmed genetically
• • Patients who have been informed and do not object to participating in the research
• Exclusion Criteria:
• • Patients who do not speak French
• • Patients who are not affiliated to a social security scheme or who are not entitled to it
• • Patients under legal protection, or under guardianship or trusteeship.